Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.46 |
| ▸ | ITGAV | P06756 | 5/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.46 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 5/20 | 0.42 |
| ▸ | MC5R | P33032 | 5/20 | 0.42 |
| ▸ | MC3R | P41968 | 5/20 | 0.42 |
| ▸ | MC1R | Q01726 | 5/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 7/20 | 0.39 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.38 |
| ▸ | GRB2 | P62993 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278822 | 0.91 | ITGB3 (0.47) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL13481626 | 0.83 | ITGB3 (0.59) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL8205616 | 0.83 | ITGB3 (0.59) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL13449397 | 0.77 | ITGB3 (0.39) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL13449462 | 0.77 | ITGB3 (0.39) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL14075704 | 0.76 | ITGB3 (0.51) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL14075695 | 0.76 | ITGB3 (0.53) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL13918138 | 0.76 | ITGB3 (0.53) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL278946 | 0.75 | ITGB3 (0.41) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL278647 | 0.75 | CACNA1B (0.46) | ITGB3ITGAVITGB1ITGA5MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133472-B2 | Cyclopeptides containing RGD mimetics as imaging markers for integrins | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100074844-A1 | Cyclopeptides Containing RGD Mimetics As Imaging Markers For Integrins | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074844-A1 | Cyclopeptides Containing RGD Mimetics As Imaging Markers For Integrins | ITGB3, ITGAV, ITGB1 | ITGB3 1/4885ITGAV 2/4885ITGB1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.